<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383977</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-OC-203</org_study_id>
    <nct_id>NCT04383977</nct_id>
  </id_info>
  <brief_title>Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg
      qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with
      platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) by investigator</measure>
    <time_frame>up to 2 years</time_frame>
    <description>ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>30 days after the last dose</time_frame>
    <description>Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by investigator</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS is the time interval from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristic</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Evaluation of PK parameters Tmax of apatinib or etoposide in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristic</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Evaluation of PK parameters Cmax of apatinib or etoposide in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristic</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Evaluation of PK parameters t1/2 of apatinib or etoposide in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristic</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Evaluation of PK parameters AUC0-t of apatinib or etoposide in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib-Etoposide capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib and Etoposide capsule</intervention_name>
    <description>Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib-Etoposide capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients, â‰¥18 Years.

          2. Epithelial ovarian, fallopian tube or primary peritoneal cancer

          3. Platinum refractory and resistant disease (disease progression during platinum therapy
             or within &lt;6 months of platinum therapy)

          4. EOCG performance status of 0-2

        Exclusion Criteria:

          1. Non-epithelial tumours

          2. Ovarian tumours with low malignant potential

          3. Surgery (including open biopsy) within 4 weeks before starting study therapy or
             anticipated need for major surgery during study treatment

          4. Evidence of rectosigmoid involvement by pelvic examination, bowel involvement on
             computed tomography, or clinical symptoms of bowel obstruction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhaoyu Zhong, M.M</last_name>
    <phone>+86 15045090779</phone>
    <email>zhongzhaoyu@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fenglin She, M.M</last_name>
    <phone>+86 18301190515</phone>
    <email>shefenglin@hrglobe.cn</email>
  </overall_contact_backup>
  <link>
    <url>https://prsinfo.clinicaltrials.gov/results_definitions.html</url>
    <description>ClinicalTrials.gov Results Data Element Definitions for Interventional and Observational Studies</description>
  </link>
  <link>
    <url>https://prsinfo.clinicaltrials.gov/results_table_layout/ResultSimpleForms.html</url>
    <description>Checklists, templates, and examples to help gather information needed to report results to ClinicalTrials.gov</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

